Lyrica
Top Ten most popular articles on Pharmafile.com this week
July 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biohaven, FDA, Lyrica, NICE, Pfizer, UK, US, pharma, top ten
At the end of a week that could certainly be called “eventful” here in the UK – one that saw …
FDA approves nine generic versions of Pfizer’s Lyrica
July 23, 2019Manufacturing and Production, Sales and Marketing FDA, Lyrica, Pfizer, pharma
The FDA has given its approval to the first generic versions of Pfizer’s Lyrica (pregabalin), it has emerged, giving the …
Pfizer’s Lyrica fails at Phase 3 in treating primary generalised tonic-clonic (PGTC) seizures
May 28, 2019Manufacturing and Production, Research and Development, Sales and Marketing Lyrica, Pfizer, epilepsy, pharma, trial failure
Pfizer has unveiled new Phase 3 data on the effectiveness of Lyrica (pregabalin) in the adjunctive treatment of primary generalised …
Lyrica to be made class C drug in Northern Ireland
April 1, 2019Sales and Marketing Lyrica, Northern Ireland, class c, illegal drugs, pain, pregabalin
Pregabalin – sold under the brand name Lyrica – will now be treated as a class C drug in Northern …
Pfizer defeated in Britain’s highest court over Lyrica patent
November 15, 2018Business Services, Medical Communications Legislation, Lyrica, Pfizer, court, pharma
American pharma firm Pfizer have lost in the final round of a protracted court battle over the patent on epilepsy …
Pfizer’s Lyrica achieves endpoint as adjunct in paediatric epilepsy
May 18, 2018Medical Communications, Research and Development FDA, Lyrica, Pfizer, epilepsy, pharma
Pfizer has revealed new Phase 3 data for its oral epilepsy therapy Lyrica (pregbalin) as an adjunctive treatment for partial …
Pfizer loses UK patent infringement case over $5.1bn drug
October 13, 2016Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, patent infringement, pregabalin
Pfizer has been dealt a significant blow as the UK Court of Appeal has rejected the company’s patent infringement claims …
Pfizer raised 100 US drug prices 1 January
January 12, 2016Manufacturing and Production, Sales and Marketing Allergan, Drug pricing, Lyrica, Pfizer, ibrance, tax inversion
Drugs giant Pfizer raised the prices of more than 100 of its drugs in the US on 1 January, in …
Legal analysis: a summary of the Lyrica pregabalin case and the issue of cross-label use in Europe
October 2, 2015Medical Communications Lyrica, Pfizer
The Warner Lambert v Actavis pregabalin cases have been before the UK Courts on no less than seven occasions since the beginning of …
High Court rules against Pfizer in Lyrica patent case
September 10, 2015Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, anxiety, epilepsy, generics, neuropathic pain, pregabalin
The High Court of England and Wales today ruled against Pfizer in the patent battle with Actavis on Pfizer’s blockbuster …
Pfizer offers to pay for UK Lyrica switches
August 13, 2015Lyrica, NHS England, Pfizer, generics, neuropathic pain, patents, pregabalin
Pfizer is to pay the administrative costs of GPs to switch patients to Lyrica from generic versions of pregabalin, as …
Big-name generics among new CHMP recommendations
April 27, 2015Sales and Marketing CHMP, EMA, European Medicines Agency, Lyrica, pregabalin
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended 11 new medicines for approval, among them several …
Generic version of Pfizer’s Lyrica launched
March 25, 2015Sales and Marketing CCG, Lyrica, NHS, Pfizer, consilient health, pregabalin, rewisca
A UK pharma firm has launched a cut-price version of Pfizer’s Lyrica along with a bespoke supply chain to ensure …
Blow for Pfizer as Lyrica misses target
March 13, 2015Sales and Marketing FDA, Lyrica, Pfizer, fibromyalgia, pain, pregablin
A late-stage study of Pfizer’s Lyrica has failed to demonstrate it has any significant pain reduction in patients with fibromyalgia. …
New Lyrica formulation effective in trials
December 19, 2014Sales and Marketing HIV, Lyrica, Pfizer, pain, pregabalin, shingles
Pfizer has reported positive Phase III results for a new formulation of its painkiller Lyrica. In the study, a controlled-release …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
